Pennant Investors’s Travere Therapeutics TVTX Stock Holding History

Pennant Investors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-55,800	Closed	-$459K	–	43
2024 Q2	$459K	Buy	+55,800	New	+$376K	0.12%	23
2024 Q1	–	Sell	-55,800	Closed	-$502K	–	46
2023 Q4	$502K	Buy	+55,800	New	+$406K	0.11%	20

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pennant Investors's TVTX Position: Q3 2024 in Review

Pennant Investors sold out of Travere Therapeutics (TVTX) in Q3 2024, closing a stake of 55,800 shares — an estimated $459K sold.

Pennant Investors first reported a position in TVTX in Q4 2023 and held it in 2 quarters. The position peaked at $502K in Q4 2023. 178 funds tracked by Wall St. Rank hold TVTX as of Q3 2024.

Pennant Investors reported no remaining Travere Therapeutics position as of Q3 2024 after selling out during the quarter.
Pennant Investors sold 55,800 Travere Therapeutics shares in Q3 2024, an estimated $459K.
Pennant Investors first reported a position in Travere Therapeutics in Q4 2023 and held it in 2 quarters.
Pennant Investors's Travere Therapeutics position peaked at $502K in Q4 2023.
178 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.